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The function of ductus arteriosus closes within a few minutes to a few days after birth in term 
neonates. In some cases, the duct remains open after birth, a condition which is called patent ductus 
arteriosus (PDA). PDA is associated with high rates of neonatal mortality and morbidity. The present 
study aims to evaluate the effect of oral ibuprofen on closure of PDA in term neonates.  
Materials and Methods 
In this clinical trial, 40 neonates (at the gestational age of 37 weeks and more) aged 5 to 30 days, with 
confirmed PDA through echocardiography, were randomly divided into two groups (n= 20). One 
group received ibuprofen syrup (10 mg/kg body weight) in the first 24 hours, followed by 5 mg/kg 
body weight for the next four days. The other group received placebo in the same manner. On the 
seventh day after the beginning of intervention, neonates underwent echocardiography for 
examination of PDA closure. Side effects of ibuprofen were evaluated. Symptoms of kidney failure, 
such as oliguria, edema, and proteinuria and increased creatinine, as well as gastrointestinal side 
effects such as gastrointestinal bleeding and recurrent vomiting, were assessed for one month.   
Results 
According to the results, PDA diameter was not significantly different in ibuprofen compared to the 
placebo groups before (p>0.05) and after (p>0.05) intervention. Frequency of PDA closure was 13 
(65%) in the ibuprofen group and 10 (50%) in the placebo group with no significant difference 
(p>0.05). There was no significant difference in the mean systolic and diastolic pressure gradient after 
intervention and in mean changes in pulmonary arterial hypertension between the two groups 
(p>0.05). No side effects were observed in any of the groups.  
Conclusion: Based on the results, oral ibuprofen did not significantly affect PDA closure in term 
neonates.   
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1- INTRODUCTION 
     The ductus arteriosus is a blood vessel 
that connects the pulmonary artery to the 
aorta. In the mother’s uterus, blood is 
shunted from the pulmonary aorta due to 
higher pressure in the lungs. Therefore, 
blood exits from the right ventricle and 
enters the ductus arteriosus through which 
it can finally enter the aorta. 
Prostaglandins are strong vasodilators that 
keep the ductus arteriosus open in the 
uterus. In normal conditions, the resistance 
of the pulmonary artery gradually 
decreases after birth under the influence of 
respiratory oxygen. Subsequently, blood 
enters the pulmonary circulation and takes 
the prostaglandins into the lungs, where 
they metabolize and eliminate from the 
circulation. Oxygenated blood also plays 
an important role in the closure of the 
ductus arteriosus. Normal fetal circulation 
depends on the placenta and patent ductus 
arteriosus (PDA), and changes after birth 
due to placenta abruption and the onset of 
pulmonary circulation. The ductus 
arteriosus immediately starts to close after 
birth (1, 2).  
The equilibrium between the contractile 
effects of oxygen and dilating effects of 
prostaglandin plays an essential role in the 
PDA (3). The effects of these substances 
depend on the intrauterine age of the 
neonate; in preterm neonates, the 
susceptibility of the ductus arteriosus to 
the effects of prostaglandin-induced PDA 
is higher, yet decreases as age advances. 
Therefore, PDA prevalence is high in 
preterm infants, and up to 65% in 
extremely premature infants (4). In term 
neonates with normal birth weight, the 
ductus arteriosus usually closes within 
three days after birth (5). The PDA occurs 
in 1 term neonate per 2,000 live births (6). 
The clinical outcome of PDA is associated 
with the size of left-to-right shunt through 
the ductus arteriosus, which is related to 
changes in blood flow in the lungs, 
kidneys, and intestines (7-11). Currently, 
the first choice of treatment for PDA in 
preterm infants is drug therapy using 
cyclooxygenase inhibitors (12). The use of 
injectable or oral indomethacin for closure 
of ductus arteriosus has led to successful 
non-surgical closure of PDA in many 
neonates (15-13). However, indomethacin 
therapy is associated with adverse 
complications such as decreased cerebral, 
mesenteric, and renal perfusion (16, 17). 
Ibuprofen has been considered as a 
possible alternative to indomethacin (18-
23). Available evidence shows a 
comparable rate of PDA closure after 
ibuprofen therapy (24-26).  
Unlike indomethacin, Ibuprofen has a 
lower effect on urine output and renal 
function (18, 19). Additionally, ibuprofen 
has a greater effect on brain blood flow, 
but has not yet been reported to reduce 
intraventricular hemorrhage (IVH) risk 
(20, 22, 23). Because of the availability 
and cost-effectiveness of oral ibuprofen 
compared to injectable ibuprofen, many 
physicians use this therapeutic regimen to 
close PDA (16, 17, 27). If drug therapy is 
not possible or successful, surgery or coil 
catheterization can be performed. PDA is 
due to physiological developmental 
disorder in preterm infants, whereas 
abnormal PDA closure is associated with a 
major structural anomaly in term neonates.  
For term neonates, treatments of choice 
include catheterization and surgery, of 
which catheterization is preferred due to 
fewer complications and shorter recovery 
time. Indomethacin is not effective in 
treating PDA in term neonates, and, 
therefore, is not recommended for this 
purpose (12). The use of intravenous or 
oral indomethacin and ibuprofen has been 
approved for preterm infants, but their use 
for term neonates has only been 
investigated in experimental research. 
Currently, the traditional treatment of PDA 
in term neonates is surgery, which is 
associated with high rates of mortality and 
morbidity and huge costs (28). Adverse 
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effects such as recurrent laryngeal nerve 
injury, chylothorax (thoracic duct injury), 
and pneumothorax have also been reported 
(29). As for the coil catheterization, the 
shunt is more likely to remain after the 
closure of the large arterial duct, which in 
some cases leads to the destruction of red 
blood cells and consequently, hemolysis 
and acute renal failure (30). Besides, coil 
embolization into the pulmonary 
circulation is likely done in the large 
arterial duct (31). Nevertheless, few 
studies have been conducted on the 
efficacy of cyclooxygenase inhibitors such 
as ibuprofen for the closure of PDA in 
term neonates (28). Since previous studies 
have come up with controversial findings, 
and ibuprofen remains to be used as a 
widely acceptable treatment for PDA in 
term neonates, further studies are needed 
to prove or rule out ibuprofen's efficacy 
and provide evidence to support or reject 
ibuprofen therapy for PDA in term 
neonates, in order to minimize the use of 
catheterization and surgical procedures and 
associated risks. This study is aimed to 
investigate the effect of oral ibuprofen as a 
safer, cheaper, and more available method 
for treating PDA in term neonates. 
2- MATERIALS AND METHODS 
2-1. Study design  
      The present study is a clinical trial 
(IRCT20190204042618N1), performed on 
40 neonates referred to Imam Ali Clinic or 
admitted to Hajar Hospital in Shahrekord, 
Iran.  
2-2. Methods  
The samples were gradually selected by 
simple convenience sampling. Term 
infants (at the gestational age of 37 weeks) 
aged 5 to 30 days showing PDA symptoms 
such as tachycardia, full pulses, decreased 
blood oxygen saturation, hemodynamic, 
respiratory, murmur, and other problems 
related to the ductus arteriosus by the 
physician decision, underwent 
echocardiography.  
2-3. Measuring tool  
After confirmation of PDA by 
echocardiographic examination and 
measurement of the ductus arteriosus size, 
systolic and diastolic blood pressure 
gradient, pulmonary hypertension, and 
other inclusion criteria in the neonates 
were examined. The neonates were 
randomly divided into two groups (n= 20). 
Physical examinations were performed for 
signs of congestive heart failure including 
cardiomegaly, tachycardia and tachypnea 
tachycardia, gallop rhythm, dyspnea, 
tachypnea, and heart murmur in both 
groups. Intervention group received the 
oral ibuprofen syrup and control group 
received placebo only. 
2-4. Intervention 
Intervention group received oral ibuprofen 
(initial dose of 10 mg/kg/day, then four 
doses of 5 mg/kg/day for the next four 
days). Control group received placebo in 
the same manner. The neonates were 
examined for the side effects of the drug, 
including gastrointestinal, renal, dermal, 
and other potential complications. The 
drug was given by the mothers on the 
advice of the researcher, but the echo 
technician did not know the type of drug 
administered and echocardiography was 
performed in two different centers. 
2-5. Ethical considerations  
The study protocol was approved by the 
Ethics Committee of Shahrekord 
University of Medical Sciences (Ethics 
code: IR.SKUMS.REC.1397.1). It should 
be noted that the development of any of 
the complications is indicated in the 
patient's symptoms, and in case of 
outpatient visits, parents were advised to 
refer to the specialist if they noticed any 
changes in their infant's conditions. 
Echocardiography was performed on all 
infants seven days after beginning of the 
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intervention and the size of the ductus 
arteriosus, systolic and diastolic blood 
pressure gradient, and pulmonary 
hypertension were examined. If the ductus 
arteriosus had closed and no other 
complication was developed after the first 
therapeutic intervention, an additional 
ibuprofen therapeutic regimen would start 
in the similar scheme to the first. 
Echocardiography was then performed 
again in this group at 30 days of age to 
examine the closure of PDA. 
2-6. Inclusion and exclusion criteria 
The infants were included in the study by 
the parents’ consent for their participation. 
The infants would be excluded if they had 
gastrointestinal bleeding, increased 
creatinine, and decreased urine output. 
3- RESULTS 
      In this clinical trial, with the aim of 
investigating the effect of oral ibuprofen 
on PDA closure in term neonates, 40 
neonates (at the gestational age of 37 
weeks and over) aged 5 to 30 days who 
had PDA were randomly assigned into two 
groups (n= 20). One group received 
ibuprofen tablets (10 mg/kg/day on the 
first day and 5 mg/kg/day in the next four 
days), and one group was given a placebo 
syrup. The general characteristics of the 
patients in the two groups are presented in 
Table.1 and Figure.1. There was no 
significant difference in gestational age, 
chronological age and weight between the 
two groups (p<0.05). There was also no 
significant difference in gender between 
the two groups (p>0.05, Figure.1). 
 




Mean ± SD Mean ± SD 
Gestational age 1.2±38.65 1.4±38.55 0.69 
Chronological age 4.15±11.15 5.41±13.35 0.19 
Weight (g) 698±3040 442±3042 0.06 


















Fig.1: Qualitative general characteristics (gender) of the patients under study.  
Asadpour et al. 
Int J Pediatr, Vol.8, N.9, Serial No.81, Sept. 2020                                                                                          11905 
The results regarding the frequency and 
percentage of closure of the PDA on the 
7th day after the beginning of the 
intervention in the studied groups are 
shown in Figure.2. In our study, PDA 
closure occurred in 13 patients (65%) in 
the case group and 10 (50%) in the placebo 
group with no statistically significant 
difference (p<0.05). As previously 
mentioned, in case of PDA closure after 
the first therapeutic regimen and no drug-
related complications, an additional 
regimen was performed in the ibuprofen 
group similar to the first regimen. 
Afterwards, echocardiography was 
performed again at 30 days of age in the 
ibuprofen group to examine PDA closure. 
The results showed that PDA closed after 
the second therapeutic regimen at age 30 
days in two out of seven neonates (28.6%) 
in the ibuprofen group whose ductus 
arteriosus had remained open after the first 
therapeutic regimen. The diameter of PDA 
in the group receiving ibuprofen and the 
control group were not significantly 
different before and after the intervention 
(p>0.05, Table.2). The decrease in the 
diameter of PDA after intervention was 
more pronounced in the ibuprofen group 
than in the control group by an average of 
0.57 mm, but the difference in PDA 
reduction between the two groups was not 
statistically significant. No 
gastrointestinal, renal, and skin 
complications were observed in either of 
the groups after intervention. 
 
 
Fig.2: Frequency and percentage of patent ductus arteriosus closure after intervention in the studied 
groups. 
 
      Table-4: Comparison of mean patent ductus arteriosus diameter before and after intervention.  
P value 
Control, n=20 
Mean ± SD 
Ibuprofen, n=20 
Mean ± SD 
Variables 
0.18 0.40±2.53 0.33±2.7 PDA diameter (mm) before intervention 
0.34 1.23±1.15 1.11±0.75  PDA diameter (mm) after intervention 
0.09 1.16±1.38 1.06±1.95 Change of PDA diameter (mm)  
  PDA: Patent ductus arteriosus, SD: Standard deviation. 
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4- DISCUSSION 
       The present study aimed to evaluate 
the effect of oral ibuprofen on closure of 
PDA in term neonates. PDA diameter was 
not significantly different between 
ibuprofen and placebo groups before and 
after intervention. Frequency of PDA 
closure was 13 (65%) in the ibuprofen 
group and 10 (50%) in the placebo group 
with no significant difference. Usually, in 
term neonates the ductus arteriosus closes 
within a few days after birth. In some 
cases, however, it is does not, a condition 
which is referred to as PDA (32). The 
incidence rate of PDA in term neonates 
varies from 1 in 2000 to 1 in 2500 (33). 
Mortality and morbidity in neonates with 
PAD are increased due to heart failure and, 
in rare cases, infective endocarditis. In 
addition, pulmonary vascular disease may 
also develop in these patients. Ductus 
arteriosus closure is important in treatment 
of cardiovascular and respiratory problems 
in neonates (34). Therefore, more clinical 
trials are needed to recommend certain 
drugs such as indomethacin and ibuprofen 
for closure of PDA in term neonates (28).  
In the present study, PDA closed in 13 
neonates (65%) receiving ibuprofen and 10 
(50%) receiving placebo on the 7th day 
after the beginning of intervention. In our 
study, which is consistent with the study of 
Amoozgar et al. (28), the rate of PDA 
closure was higher in the ibuprofen group 
than in the placebo group, but the 
difference was not statistically significant, 
probably due to the lower sample size and 
the higher age of neonates in our study 
compared to Amoozgar et al. These 
inconsistencies in the findings suggest that 
the effect of ibuprofen on PDA closure 
may vary on different days after the onset 
of intervention. In our study, ibuprofen did 
not cause any side effects, which is 
consistent with the findings of Amoozgar 
et al. (28). The findings of Pour Arian et 
al. (2015) were compared with those of the 
study by Amoozgar et al. using the 
standard dose of ibuprofen. The 29 
neonates in the study of Pour Arian et al. 
received the highest dose of ibuprofen 
(initial dose of 20 mg/kg on the first day, 
two doses of 10 mg/kg /day in the next two 
(second and third) days). In 18 newborns, 
the PDA closed 4 days after the beginning 
of the treatment (62.1% vs. 43.3% for 
standard dose and 4.7% for the control 
group in the previous study). In our study, 
this rate was 65% on day 7, which is 
roughly the same as the rate in the study of 
Pour Arian et al. Despite the high dose of 
ibuprofen used in the study of Pour Arian 
et al., the similarity of PDA closure rate in 
both studies is probably due to the longer 
period of treatment in our study.  
Similarly, although the ibuprofen 
administered in the study of Pour Arian et 
al. was twice the dose of our study, PDA 
size decreased by 1.95 mm in our study 
compared 1.32 mm in that of Pour Arian et 
al. This may be due to the fact that, 
although our administered dose was half 
the dose of Pour Arian et al., the drug was 
administered for 5 days in our study but 
only for 3 days in the study by Pour Arian 
et al.  (37). In our study, PDA closed in 
65% of the neonates in the ibuprofen 
group and 50% in the control group with 
no statistically significant difference, 
which is similar to the study by Alipour et 
al. It appears that the lack of significant 
effects of ibuprofen in our study was due 
to the small sample size.  
In the study of Alipour et al. where the 
sample size was larger, this result was 
probably due to delayed echocardiography 
and examination of PDA closure (on day 
21) compared to other studies (38). In a 
study by Yantie et al. (2017) in Indonesia, 
term neonates with PDA were divided into 
two groups (n: 16): the case group 
(receiving ibuprofen at 10 mg/kg on the 
first day, and two doses of 5 mg/kg/day in 
the next two days) and the control group 
(receiving placebo). PDA closed in 8 
neonates in the ibuprofen group and 10 in 
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the control group with no statistically 
significant difference. In our study, PDA 
closed in 13 neonates in the ibuprofen 
group and 10 neonates in the control group 
with no statistically significant difference 
(39). It should be noted that in the 
mentioned study, the sample size was also 
small (in each group included 16 
neonates). The sample size in a study by 
Deng et al. (40) was similar to our study, 
and the times of echocardiography and the 
examination for PDA closure were almost 
the same in both. Contrary to our study, 
however, the rate of PDA closure was 
significantly different between 
indomethacin (76%) and control (25%) 
groups. In our study, the rate of PDA 
closure was 65% in the ibuprofen group 
and 50% in the control group without any 
statistically significant difference. In many 
studies as already mentioned, ibuprofen 
has been observed to have a similar 
efficacy as indomethacin in preterm 
neonates (23, 24).  
However, compared to those, 
indomethacin was found to be highly 
efficient to close the PDA in term 
neonates, whereas ibuprofen was not as 
effective. More studies are needed on the 
effects and efficacy of different drugs in 
term neonates. Drug responses can also 
vary in different individuals. For example, 
genetic polymorphism can cause different 
clinical responses and side effects in 
different individuals. Pharmacokinetic and 
pharmacodynamic characteristics of 
ibuprofen in full-term infants can have an 
impact on the interpersonal differences in 
response to the drug (39).  
It should therefore be noted that, despite 
the similarities in their design, the cited 
study was conducted in China and ours in 
Iran, and the genetic differences in drug 
responses of the two studies might have 
led to different rates of drug response and, 
subsequently, different observations in the 
two studies. In our study, no 
gastrointestinal, renal or skin 
complications were observed in any of the 
samples, which is consistent with other 
studies with ibuprofen. Finally, the 
differences in the findings of the two 
studies might be due to differences in 
study populations, sample size, dosage, 
and the duration of the therapeutic 
regimen, as well as difference in the time 
of echocardiography. However, since 
ibuprofen did not cause any side effects in 
our study, it can be further studied for 
PDA closure treatment in term neonates 
before surgery. 
5- CONCLUSION 
      According to the results of this study, 
there was no significant difference in PDA 
closure rate and mean change in PDA 
diameter between ibuprofen and placebo 
groups. In addition, there was no 
significant difference in mean changes in 
systolic and diastolic pressure gradient and 
mean change in pulmonary hypertension 
between the two groups after intervention. 
Finally, the results of this study showed 
that oral administration of ibuprofen did 
not significantly affect PDA closure in 
term neonates. 
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